Company attributes
Other attributes
GenapSys aims to democratize access to Next-Generation Sequencing in order to advance genomics discovery, biomedical research, healthcare, diagnostics, agriculture and other fields.
GenapSys’s priority is to help researchers and clinicians have access to accurate and affordable sequencing at a point closer to patients in order to better treat cancer patients and also fight pandemic outbreaks such as COVID-19 caused by SARS-CoV-2. Other areas with applications to sequencing include food science, personalized medicine and forensics.
GenapSys announced in February, 2020, the launch of its gene sequencer in the Asia Pacific region of Korea, Singapore, Japan and China, in the midst of the Coronavirus outbreak. The company has expanded with 25 distributorship deals and $75 million in financing to scale its global presence. Sequencing is used to study strains and gene mutations in infected individuals to better understand the origin of the virus and containment strategies.
